Crinetics Pharmaceuticals (CRNX) Net Cash Flow (2017 - 2026)

Crinetics Pharmaceuticals' Net Cash Flow history runs 10 years deep, the most recent figure standing at $12.8 million for Q1 2026.

• In Q1 2026, Net Cash Flow rose 107.54% year-over-year to $12.8 million; the TTM figure through Mar 2026 stood at $19.4 million (up 106.43% YoY), while the FY2025 annual figure was -$163.4 million, down 177.94% from the prior year.
• Net Cash Flow for Q1 2026 stood at $12.8 million, up from -$9.8 million in the prior quarter.
• The five-year high for Net Cash Flow was $341.0 million in Q1 2024, with the low at -$170.0 million in Q1 2025.
• The 5-year median for Net Cash Flow is -$9.8 million (2025), against an average of -$5.1 million.
• Peak annual rise in Net Cash Flow reached 3902.19% in 2024, while the deepest fall reached 5613.71% in 2024.
• Crinetics Pharmaceuticals' Net Cash Flow stood at $1.8 million in 2022, then sank by 5091.37% to -$87.9 million in 2023, then soared by 40.02% to -$52.7 million in 2024, then jumped by 81.49% to -$9.8 million in 2025, then jumped by 231.29% to $12.8 million in 2026.
• Business Quant data shows CRNX's Net Cash Flow at $12.8 million in Q1 2026, -$9.8 million in Q4 2025, and $57.2 million in Q3 2025.